Clin2
NCT06647069Possibly a fitRecruiting

Testing a new drug for lupus and rheumatoid arthritis

Systemic Lupus Erythematosus (SLE)Rheumatoid Arthritis (RA)

Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.

This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
62 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You must have either systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), diagnosed by standard criteria.
  • For lupus: Your disease must be moderately to severely active, with a score of at least 8 on a standard activity scale, and you must have had a poor response to at least one treatment besides antimalarials.
  • For rheumatoid arthritis: Your disease must be moderate to severe (based on joint counts and a disease activity score), and you must have tried and failed or not tolerated at least 2 prior drugs, including at least one biologic or targeted synthetic drug.
  • You must use effective birth control during and for at least 140 days after the last dose. Women must have a negative pregnancy test before starting.
  • You cannot have certain other serious health conditions, active infections, or have received certain strong medications or procedures within specific timeframes.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07447986Recruiting· Phase 2
Testing a New Injection for Lupus (SLE)

This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.

Beijing, Beijing Municipality
NCT07377773Not yet recruiting· Phase 2
Investigational drug for moderate-to-severe rheumatoid arthritis

This trial tests an investigational drug for people with moderate-to-severe rheumatoid arthritis who haven't responded well to previous treatments. It aims to see if the drug can reduce joint pain and swelling.

NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants

This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.

La Jolla, California
NCT07276958Recruiting· Phase 1
Study of LY4298445 for lupus and rheumatoid arthritis

This study tests an investigational drug called LY4298445 in healthy people and in people with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). It aims to see if the drug is safe and how the body handles it.

Brisbane
NCT06977724Recruiting· Phase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis

This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.

Avon Park, Florida
NCT06841042Recruiting· Phase 1/Phase 2
Testing a new drug for active lupus

This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.

Beijing

Hear when a new Systemic Lupus Erythematosus (SLE) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.